Tvardi Therapeutics plans 2027 mid-to-late stage ulcerative colitis trial for STAT3 inhibitor TTI-109
TVRD•Market opportunity cited by Tvardi
Tvardi pegged the addressable ulcerative colitis market at about USD 3 billion in the U.S. and USD 9 billion globally, citing high non-remission rates.
Planned 2027 patient study and upcoming webinar
A patient study in moderate-to-severe ulcerative colitis is planned for 2027, pending IND clearance and additional funding, with safety primary and 12-week remission secondary.
Management will present new ulcerative colitis data in a KOL webinar on Aug. 19, positioning TTI-109 against sub-30% placebo-adjusted remission rates for current therapies.
Ulcerative colitis chosen as lead indication for TTI-109
Tvardi Therapeutics selected ulcerative colitis as the lead indication for its oral STAT3 inhibitor TTI-109 following a completed Phase 1 healthy-volunteer study.
Phase 1 results have already been presented, showing broad immune modulation consistent with mechanisms implicated in ulcerative colitis, without detailing trial metrics.
